Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC.ARWR · Entity 3472 | Director | August 18, 2026 | August 20, 2026 |
| AVITA Medical, Inc.RCEL · Entity 5905 | Director | November 21, 2022 | November 22, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARROWHEAD PHARMACEUTICALS, INC.
Report date August 18, 2026 · Filed August 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 111,459 |
Reported balance
After 2026-08-18 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-18 · Sale · Disposed 11,600 · Balance 111,459 F1: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $87.20 to $87.44, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F2: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $87.20 to $87.44, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F2: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.
AVITA Medical, Inc.
Report date November 21, 2022 · Filed November 22, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 229,543 |
Last balance in matching sequence
After 2022-11-21 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2022-11-21 · Exercise / conversion · Acquired 150,000 · Balance 379,543 F1: The exercise price was converted from A$8.20, which reflects the 100:1 consolidation ratio applied in converting ordinary shares of Predecessor (as defined below) to shares of the Issuer's Common Stock, using the exchange rate as published by the Reserve Bank of Australia in effect on the date of grant (November 30, 2018). F2: Includes 634,602 of the Issuer's CHESS Depositary Interests ("CDIs"). CDIs are units of beneficial ownership in shares of common stock of the Issuer that are publicly traded on the Australian Securities Exchange (the "ASX") and held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX. Five CDIs are equivalent to one share of Common Stock and have all the rights and privileges of Common Stock. The Reporting Person holds 634,602 CDIs, which translate into 126,920 of the shares of Common Stock set forth above. Row 2 · 2022-11-21 · Sale · Disposed 150,000 · Balance 229,543 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.05 to $7.45. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of the shares of Common Stock sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: Includes 634,602 of the Issuer's CHESS Depositary Interests ("CDIs"). CDIs are units of beneficial ownership in shares of common stock of the Issuer that are publicly traded on the Australian Securities Exchange (the "ASX") and held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX. Five CDIs are equivalent to one share of Common Stock and have all the rights and privileges of Common Stock. The Reporting Person holds 634,602 CDIs, which translate into 126,920 of the shares of Common Stock set forth above. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.99 · Expires 2022-11-27 | Direct | 0 |
Reported balance
After 2022-11-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-11-21 · Exercise / conversion · Disposed 150,000 · Balance 0 F4: These Stock Options were originally exercisable for ordinary shares of of AVITA Medical, Ltd., an Australian public company and predecessor to the Issuer ("Predecessor"). Pursuant to a scheme of arrangement, completed on June 30, 2020, the Stock Options became exercisable for shares of Common Stock of the Issuer in the ratio of one share of Common Stock for every 100 ordinary shares of Predecessor for which the Stock Options would otherwise have been exercisable. F1: The exercise price was converted from A$8.20, which reflects the 100:1 consolidation ratio applied in converting ordinary shares of Predecessor (as defined below) to shares of the Issuer's Common Stock, using the exchange rate as published by the Reserve Bank of Australia in effect on the date of grant (November 30, 2018). |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price was converted from A$8.20, which reflects the 100:1 consolidation ratio applied in converting ordinary shares of Predecessor (as defined below) to shares of the Issuer's Common Stock, using the exchange rate as published by the Reserve Bank of Australia in effect on the date of grant (November 30, 2018).
F2: Includes 634,602 of the Issuer's CHESS Depositary Interests ("CDIs"). CDIs are units of beneficial ownership in shares of common stock of the Issuer that are publicly traded on the Australian Securities Exchange (the "ASX") and held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX. Five CDIs are equivalent to one share of Common Stock and have all the rights and privileges of Common Stock. The Reporting Person holds 634,602 CDIs, which translate into 126,920 of the shares of Common Stock set forth above.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.05 to $7.45. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of the shares of Common Stock sold at each separate price within the ranges set forth in this footnote to this Form 4.
F4: These Stock Options were originally exercisable for ordinary shares of of AVITA Medical, Ltd., an Australian public company and predecessor to the Issuer ("Predecessor"). Pursuant to a scheme of arrangement, completed on June 30, 2020, the Stock Options became exercisable for shares of Common Stock of the Issuer in the ratio of one share of Common Stock for every 100 ordinary shares of Predecessor for which the Stock Options would otherwise have been exercisable.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Armata Pharmaceuticals, Inc.
Report date December 31, 2019 · Filed February 14, 2020
Section 16 reporting ended · disclosed 2020-02-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Warrant to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.32 · Expires 2021-11-22 | IndirectSee Footnote | 0 |
Reported balance
After 2019-05-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-05-09 · Other · Disposed 46,666 · Balance 0 F4: Price reported is reflective of adjustments made to the exercise price after the date of issuance pursuant to the terms of the warrant. F1: The reported securities were redeemed by the issuer for $12,065.46. F2: The number of shares of common stock for which the warrant was exercisable does not reflect the 1-for-14 reverse stock split that was effected on May 9, 2019. F3: The warrant was held by One Funds Management Limited as Trustee for Asia Pacific Healthcare Fund II ("One Funds Management"). The Reporting Person may be deemed to have shared voting and dispositive power over the shares beneficially owned by One Funds Management but disclaims such beneficial ownership, except to the extent of his pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities were redeemed by the issuer for $12,065.46.
F2: The number of shares of common stock for which the warrant was exercisable does not reflect the 1-for-14 reverse stock split that was effected on May 9, 2019.
F3: The warrant was held by One Funds Management Limited as Trustee for Asia Pacific Healthcare Fund II ("One Funds Management"). The Reporting Person may be deemed to have shared voting and dispositive power over the shares beneficially owned by One Funds Management but disclaims such beneficial ownership, except to the extent of his pecuniary interest therein, if any.
F4: Price reported is reflective of adjustments made to the exercise price after the date of issuance pursuant to the terms of the warrant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 18, 2026 Filed Aug 20, 2026 21:22 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 11,600 | $87.30 | $1,012,680.00 |
DisclosureSEC source: 0001250379-26-000002 · wk-form4_1787260939.xml · nonDerivative · entry 1 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,459 F1 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $87.20 to $87.44, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 23:40 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 7,819 | $0.00 | $0.00 |
DisclosureSEC source: 0001250379-25-000005 · wk-form4_1766101205.xml · nonDerivative · entry 1 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,059 F1 · shares: Represents shares underlying restricted stock units, which shares will vest in one installment on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such date. Read SEC document |
| December 05, 2025 Filed Dec 9, 2025 23:04 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 16,250 | $61.03 | $991,737.50 |
DisclosureSEC source: 0001250379-25-000003 · wk-form4_1765321464.xml · nonDerivative · entry 1 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,240 F1 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $60.90 to $61.54, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Read SEC document |
| December 18, 2024 Filed Dec 20, 2024 23:04 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 16,733 | $22.99 | $384,691.67 |
DisclosureSEC source: 0001628280-24-052269 · wk-form4_1734735879.xml · nonDerivative · entry 1 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,490 F1 · shares: Represents shares underlying restricted stock units, which shares will vest in one installment on the first anniversary date. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 20:55 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 14,987 | $25.41 | $380,819.67 |
DisclosureSEC source: 0001628280-23-041967 · wk-form4_1703019289.xml · nonDerivative · entry 1 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,754 F1 · shares: Represents shares underlying restricted stock units, which will vest in one installment on the first anniversary of the grant date. Read SEC document |
| January 10, 2023 Filed Jan 12, 2023 01:32 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock · Derivative | 4,593 | $0.00 Strike: $33.03 | $0.00 |
DisclosureSEC source: 0001209191-23-003077 · doc4.xml · derivative · entry 2 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,593 Underlying: Common Stock · 4,593 shares Expires 2033-01-10 F2 · shares: Represents options, which will vest in one installment on the first anniversary of the grant date. Read SEC document |
| January 10, 2023 Filed Jan 12, 2023 01:32 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 7,867 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-003077 · doc4.xml · nonDerivative · entry 1 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,767 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. Read SEC document |
| November 21, 2022 Filed Nov 22, 2022 21:46 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | Exercise / conversionStock Options (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $5.99 | $0.00 |
DisclosureSEC source: 0001209191-22-058404 · doc4.xml · derivative · entry 3 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires 2022-11-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: These Stock Options were originally exercisable for ordinary shares of of AVITA Medical, Ltd., an Australian public company and predecessor to the Issuer ("Predecessor"). Pursuant to a scheme of arrangement, completed on June 30, 2020, the Stock Options became exercisable for shares of Common Stock of the Issuer in the ratio of one share of Common Stock for every 100 ordinary shares of Predecessor for which the Stock Options would otherwise have been exercisable. F1 · derivative.exercise_price: The exercise price was converted from A$8.20, which reflects the 100:1 consolidation ratio applied in converting ordinary shares of Predecessor (as defined below) to shares of the Issuer's Common Stock, using the exchange rate as published by the Reserve Bank of Australia in effect on the date of grant (November 30, 2018). Read SEC document |
| November 21, 2022 Filed Nov 22, 2022 21:46 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | SaleCommon Stock | 150,000 | $7.18 | $1,077,000.00 |
DisclosureSEC source: 0001209191-22-058404 · doc4.xml · nonDerivative · entry 2 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,543 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.05 to $7.45. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of the shares of Common Stock sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · balance_after: Includes 634,602 of the Issuer's CHESS Depositary Interests ("CDIs"). CDIs are units of beneficial ownership in shares of common stock of the Issuer that are publicly traded on the Australian Securities Exchange (the "ASX") and held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX. Five CDIs are equivalent to one share of Common Stock and have all the rights and privileges of Common Stock. The Reporting Person holds 634,602 CDIs, which translate into 126,920 of the shares of Common Stock set forth above. Read SEC document |
| November 21, 2022 Filed Nov 22, 2022 21:46 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | Exercise / conversionCommon Stock | 150,000 | $5.99 | $898,500.00 |
DisclosureSEC source: 0001209191-22-058404 · doc4.xml · nonDerivative · entry 1 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 379,543 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price was converted from A$8.20, which reflects the 100:1 consolidation ratio applied in converting ordinary shares of Predecessor (as defined below) to shares of the Issuer's Common Stock, using the exchange rate as published by the Reserve Bank of Australia in effect on the date of grant (November 30, 2018). F2 · balance_after: Includes 634,602 of the Issuer's CHESS Depositary Interests ("CDIs"). CDIs are units of beneficial ownership in shares of common stock of the Issuer that are publicly traded on the Australian Securities Exchange (the "ASX") and held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX. Five CDIs are equivalent to one share of Common Stock and have all the rights and privileges of Common Stock. The Reporting Person holds 634,602 CDIs, which translate into 126,920 of the shares of Common Stock set forth above. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:15 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantStock Options (Right to Buy) · Derivative | 3,450 | $0.00 Strike: $12.18 | $0.00 |
DisclosureSEC source: 0001209191-22-048725 · doc4.xml · derivative · entry 2 PERRY MICHAEL S · CIK 0001250379 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,900 Underlying: Common Stock · 3,450 shares Expires 2031-12-22 F5 · kind: These Stock Options were originally granted on December 22, 2021 and vested on September 1, 2022 in connection with the satisfaction of a performance-based vesting condition. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:15 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantCommon Stock | 2,980 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-048725 · doc4.xml · nonDerivative · entry 1 PERRY MICHAEL S · CIK 0001250379 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,983 F1 · kind: These shares of Common Stock were issued upon the vesting of Restricted Stock Units ("RSUs"), which were originally granted on December 22, 2021, in connection with the satisfaction of a performance-based vesting condition. F2 · shares: These shares of Common Stock represent half of the shares of Common Stock that were issued upon the vesting of the RSUs. The other shares were transferred to the Reporting Person's former spouse pursuant to a property settlement agreement. F3 · balance_after: Includes 71,440 unvested RSUs with vesting conditions based on the Reporting Person's continued employment or the market price of the Issuer's common stock. Pursuant to a property settlement agreement, half of the shares of Common Stock underlying such RSUs will be transferred to the Reporting Person's former spouse upon the respective vesting events. F4 · balance_after: Includes 634,602 of the Issuer's CHESS Depositary Interests ("CDIs"). CDIs are units of beneficial ownership in shares of common stock of the Issuer that are publicly traded on the Australian Securities Exchange (the "ASX") and held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX. Five CDIs are equivalent to one share of Common Stock and have all the rights and privileges of Common Stock. The Reporting Person holds 634,602 CDIs, which translate into 126,920 of the shares of Common Stock set forth above. Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 21:01 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | OtherCommon Stock | 23,754 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-033585 · doc4.xml · nonDerivative · entry 1 PERRY MICHAEL S · CIK 0001250379 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,958 F1 · kind: These shares of Common Stock represent half of the shares of Common Stock that were issued upon the vesting of Restricted Stock Units ("RSUs") that were previously included in the amount of shares of Common Stock beneficially owned by the Reporting Person. Upon vesting of the RSUs, these shares of Common Stock were transferred to the Reporting Person's former spouse pursuant to a property settlement agreement. F2 · balance_after: Includes 71,440 unvested RSUs with vesting conditions based on the Reporting Person's continued employment or the market price of the Issuer's common stock. Pursuant to a property settlement agreement, half of the shares of Common Stock underlying such RSUs will be transferred to the Reporting Person's former spouse upon the respective vesting events. F3 · balance_after: Includes 634,602 of the Issuer's CHESS Depositary Interests ("CDIs"). CDIs are units of beneficial ownership in shares of common stock of the Issuer that are publicly traded on the Australian Securities Exchange (the "ASX") and held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX. Five CDIs are equivalent to one share of Common Stock and have all the rights and privileges of Common Stock. The Reporting Person holds 634,602 CDIs, which translate into 126,920 of the shares of Common Stock set forth above. Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 21:54 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | SaleCommon Stock | 10,812 | $8.74 | $94,496.88 |
DisclosureSEC source: 0001209191-22-013222 · doc4.xml · nonDerivative · entry 3 PERRY MICHAEL S · CIK 0001250379 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,712 F5 · kind: Represents shares sold in order to pay withholding taxes due in connection with the vesting of RSUs. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.42 to $8.96. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of the shares of Common Stock sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · balance_after: Includes unvested RSUs with vesting conditions based on the Reporting Person's continued employment or the market price of the Issuer's common stock. F3 · balance_after: Includes 634,602 of the Issuer's CHESS Depositary Interests ("CDIs"). CDIs are units of beneficial ownership in shares of common stock of the Issuer that are publicly traded on the Australian Securities Exchange (the "ASX") and held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX. Five CDIs are equivalent to one share of Common Stock and have all the rights and privileges of Common Stock. The Reporting Person holds 634,602 CDIs, which translate into 126,920 of the shares of Common Stock set forth above. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 21:54 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantStock Options (Right to Buy) · Derivative | 3,450 | $0.00 Strike: $12.18 | $0.00 |
DisclosureSEC source: 0001209191-22-013222 · doc4.xml · derivative · entry 4 PERRY MICHAEL S · CIK 0001250379 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,450 Underlying: Common Stock · 3,450 shares Expires 2031-12-22 F7 · kind: These Stock Options were originally granted on December 22, 2021 and vested on February 23, 2022 in connection with the satisfaction of a performance-based vesting condition. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 21:54 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantCommon Stock | 5,960 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-013222 · doc4.xml · nonDerivative · entry 2 PERRY MICHAEL S · CIK 0001250379 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,524 F4 · kind: These shares of Common Stock were issued upon the vesting of RSUs, which were originally granted on December 22, 2021, in connection with the satisfaction of a performance-based vesting condition. F2 · balance_after: Includes unvested RSUs with vesting conditions based on the Reporting Person's continued employment or the market price of the Issuer's common stock. F3 · balance_after: Includes 634,602 of the Issuer's CHESS Depositary Interests ("CDIs"). CDIs are units of beneficial ownership in shares of common stock of the Issuer that are publicly traded on the Australian Securities Exchange (the "ASX") and held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX. Five CDIs are equivalent to one share of Common Stock and have all the rights and privileges of Common Stock. The Reporting Person holds 634,602 CDIs, which translate into 126,920 of the shares of Common Stock set forth above. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 21:54 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantCommon Stock | 23,753 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-013222 · doc4.xml · nonDerivative · entry 1 PERRY MICHAEL S · CIK 0001250379 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,564 F1 · kind: These shares of Common Stock were issued upon the vesting of Restricted Stock Units ("RSUs"), which were originally granted on November 26, 2019, in connection with the satisfaction of a performance-based vesting condition. F2 · balance_after: Includes unvested RSUs with vesting conditions based on the Reporting Person's continued employment or the market price of the Issuer's common stock. F3 · balance_after: Includes 634,602 of the Issuer's CHESS Depositary Interests ("CDIs"). CDIs are units of beneficial ownership in shares of common stock of the Issuer that are publicly traded on the Australian Securities Exchange (the "ASX") and held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX. Five CDIs are equivalent to one share of Common Stock and have all the rights and privileges of Common Stock. The Reporting Person holds 634,602 CDIs, which translate into 126,920 of the shares of Common Stock set forth above. Read SEC document |
| January 07, 2022 Filed Jan 8, 2022 01:12 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 6,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-002595 · doc4.xml · nonDerivative · entry 1 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,900 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 02:30 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 272 | $66.25 | $18,020.00 |
DisclosureSEC source: 0001209191-22-001318 · doc4.xml · nonDerivative · entry 3 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,500 F1 · shares: The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 02:30 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 1,600 | $65.12 | $104,192.00 |
DisclosureSEC source: 0001209191-22-001318 · doc4.xml · nonDerivative · entry 2 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,772 F1 · shares: The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.79 to $65.56, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 02:30 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 2,628 | $64.30 | $168,980.40 |
DisclosureSEC source: 0001209191-22-001318 · doc4.xml · nonDerivative · entry 1 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,372 F1 · shares: The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.77 to $64.77, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| December 22, 2021 Filed Dec 27, 2021 21:30 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantStock Options (Right to Buy) · Derivative | 13,800 | $0.00 Strike: $12.18 | $0.00 |
DisclosureSEC source: 0001209191-21-071256 · doc4.xml · derivative · entry 6 PERRY MICHAEL S · CIK 0001250379 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,800 Underlying: Common Stock · 13,800 shares Expires 2031-12-22 F9 · derivative.exercise_date: The vesting of these Stock Options is conditioned on the market capitalizaton of the Issuer being $1.25 billion or greater for 30 consecutive calendar days on or before December 31, 2024. Upon the condition being met, a portion of the Stock Options will vest immediately and the remainder will vest in a number of annual installments depending on the year in which the condition is met. Read SEC document |
| December 22, 2021 Filed Dec 27, 2021 21:30 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantStock Options (Right to Buy) · Derivative | 13,800 | $0.00 Strike: $12.18 | $0.00 |
DisclosureSEC source: 0001209191-21-071256 · doc4.xml · derivative · entry 5 PERRY MICHAEL S · CIK 0001250379 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,800 Underlying: Common Stock · 13,800 shares Expires 2031-12-22 F8 · derivative.exercise_date: These vesting of these Stock Options is conditioned on on the market price of the Issuer's Common Stock reaching $24.36 (based upon a 10-day volume-weighted average price) by June 30, 2023. Upon the condition being met, a portion of the Stock Options will vest immediately and the remainder will vest in a number of annual installments depending on the year in which the condition is met. Read SEC document |
| December 22, 2021 Filed Dec 27, 2021 21:30 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantStock Options (Right to Buy) · Derivative | 13,800 | $0.00 Strike: $12.18 | $0.00 |
DisclosureSEC source: 0001209191-21-071256 · doc4.xml · derivative · entry 4 PERRY MICHAEL S · CIK 0001250379 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,800 Underlying: Common Stock · 13,800 shares Expires 2031-12-22 F7 · derivative.exercise_date: These Stock Options vest in four equal annual installments on December 14, 2022, 2023, 2024 and 2025. Read SEC document |
| December 22, 2021 Filed Dec 27, 2021 21:30 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantCommon Stock | 23,820 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-071256 · doc4.xml · nonDerivative · entry 3 PERRY MICHAEL S · CIK 0001250379 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,811 F6 · price: Represents an award of RSUs with vesting conditioned on the market capitalizaton of the Issuer being $1.25 billion or greater for 30 consecutive calendar days on or before December 31, 2024. Upon the condition being met, a portion of the RSUs will vest immediately and the remainder will vest in a number of annual installments depending on the year in which the condition is met. F2 · balance_after: Includes unvested RSUs. F3 · balance_after: Includes 634,602 of the Issuer's CHESS Depositary Interests ("CDIs"). CDIs are units of beneficial ownership in shares of common stock of the Issuer that are publicly traded on the Australian Securities Exchange (the "ASX") and held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX. Five CDIs are equivalent to one share of Common Stock and have all the rights and privileges of Common Stock. The Reporting Person holds 634,602 CDIs, which translate into 126,920 of the shares of Common Stock set forth above. Read SEC document |
| December 22, 2021 Filed Dec 27, 2021 21:30 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantCommon Stock | 23,820 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-071256 · doc4.xml · nonDerivative · entry 2 PERRY MICHAEL S · CIK 0001250379 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,991 F5 · price: Represents an award of RSUs with vesting conditioned on the market price of the Issuer's Common Stock reaching $24.36 (based upon a 10-day volume-weighted average price) by June 30, 2023. Upon the condition being met, a portion of the RSUs will vest immediately and the remainder will vest in a number of annual installments depending on the year in which the condition is met. F2 · balance_after: Includes unvested RSUs. F3 · balance_after: Includes 634,602 of the Issuer's CHESS Depositary Interests ("CDIs"). CDIs are units of beneficial ownership in shares of common stock of the Issuer that are publicly traded on the Australian Securities Exchange (the "ASX") and held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX. Five CDIs are equivalent to one share of Common Stock and have all the rights and privileges of Common Stock. The Reporting Person holds 634,602 CDIs, which translate into 126,920 of the shares of Common Stock set forth above. Read SEC document |
| December 22, 2021 Filed Dec 27, 2021 21:30 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantCommon Stock | 23,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-071256 · doc4.xml · nonDerivative · entry 1 PERRY MICHAEL S · CIK 0001250379 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,171 F1 · price: Represents an award of Restricted Stock Units ("RSUs"), each representing a contingent right to be issued one share of Common Stock, that are subject to time-based vesting criteria. These RSUs vest in four equal annual installments on December 14, 2022, 2023, 2024 and 2025. F2 · balance_after: Includes unvested RSUs. F3 · balance_after: Includes 634,602 of the Issuer's CHESS Depositary Interests ("CDIs"). CDIs are units of beneficial ownership in shares of common stock of the Issuer that are publicly traded on the Australian Securities Exchange (the "ASX") and held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX. Five CDIs are equivalent to one share of Common Stock and have all the rights and privileges of Common Stock. The Reporting Person holds 634,602 CDIs, which translate into 126,920 of the shares of Common Stock set forth above. F4 · balance_after: Amount in column 5 reflects a decrease of 6,267 shares of Common Stock from the total reported in the Reporting Person's Form 4 filed on September 7, 2021 (the "Prior Form 4") following the finalization of a division of property with the Reporting Person's former spouse pursuant to a property settlement agreement. The Reporting Person no longer reports as beneficially owned any securities owned by his former spouse following a separation occurring after the Prior Form 4. Read SEC document |
| September 01, 2021 Filed Sep 7, 2021 20:05 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | SaleCommon Stock | 11,220 | $20.68 | $232,029.60 |
DisclosureSEC source: 0001209191-21-054958 · doc4.xml · nonDerivative · entry 2 PERRY MICHAEL S · CIK 0001250379 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,638 F4 · kind: Represents shares sold in order to pay withholding taxes due in connection with the vesting of RSUs. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.36 to $20.82. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of the shares of Common Stock sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · balance_after: Includes 634,602 of the Issuer's CHESS Depositary Interests ("CDIs"). CDIs are units of beneficial ownership in shares of common stock of the Issuer that are publicly traded on the Australian Securities Exchange (the "ASX") and held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX. Five CDIs are equivalent to one share of Common Stock and have all the rights and privileges of Common Stock. The Reporting Person holds 634,602 CDIs, which translate into 126,920 of the shares of Common Stock set forth above. F3 · balance_after: Includes 47,507 unvested RSUs, each representing a contingent right to be issued one share of Common Stock, that are subject to time-based vesting criteria. These RSUs were originally rights to receive ordinary shares of AVITA Medical, Ltd., an Australian public company and predecessor to the Issuer ("Predecessor"). Pursuant to a scheme of arrangement, completed on June 30, 2020, such RSUs became rights to be issued shares of Common Stock of the Issuer in the ratio of one share of Common Stock for every 100 ordinary shares of Predecessor to which the holder would otherwise have been entitled. The RSUs vest on June 1, 2022. Read SEC document |
| September 01, 2021 Filed Sep 7, 2021 20:05 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantCommon Stock | 23,754 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-054958 · doc4.xml · nonDerivative · entry 1 PERRY MICHAEL S · CIK 0001250379 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,858 F1 · kind: These shares of Common Stock were issued in connection with the vesting of Restricted Stock Units ("RSUs"), which were originally granted on November 26, 2019, upon the satisfaction of a performance-based vesting condition. F2 · balance_after: Includes 634,602 of the Issuer's CHESS Depositary Interests ("CDIs"). CDIs are units of beneficial ownership in shares of common stock of the Issuer that are publicly traded on the Australian Securities Exchange (the "ASX") and held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX. Five CDIs are equivalent to one share of Common Stock and have all the rights and privileges of Common Stock. The Reporting Person holds 634,602 CDIs, which translate into 126,920 of the shares of Common Stock set forth above. F3 · balance_after: Includes 47,507 unvested RSUs, each representing a contingent right to be issued one share of Common Stock, that are subject to time-based vesting criteria. These RSUs were originally rights to receive ordinary shares of AVITA Medical, Ltd., an Australian public company and predecessor to the Issuer ("Predecessor"). Pursuant to a scheme of arrangement, completed on June 30, 2020, such RSUs became rights to be issued shares of Common Stock of the Issuer in the ratio of one share of Common Stock for every 100 ordinary shares of Predecessor to which the holder would otherwise have been entitled. The RSUs vest on June 1, 2022. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 20:06 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | SaleCommon Stock | 23,000 | $17.33 | $398,590.00 |
DisclosureSEC source: 0001209191-21-038189 · doc4.xml · nonDerivative · entry 1 PERRY MICHAEL S · CIK 0001250379 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,104 F1 · kind: Represents shares sold in order to pay withholding taxes due in connection with the vesting of Restricted Stock Units ("RSUs"). F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.11 to $17.73. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of the shares of Common Stock sold at each separate price within the ranges set forth in this footnote to this Form 4. F3 · balance_after: Includes 634,602 of the Issuer's CHESS Depositary Interests ("CDIs"). CDIs are units of beneficial ownership in shares of common stock of the Issuer that are publicly traded on the Australian Securities Exchange (the "ASX") and held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX. Five CDIs are equivalent to one share of Common Stock and have all the rights and privileges of Common Stock. The Reporting Person holds 634,602 CDIs, which translate into 126,920 of the shares of Common Stock set forth above. F4 · balance_after: Includes 47,507 unvested RSUs, each representing a contingent right to be issued one share of Common Stock, that are subject to time-based vesting criteria. These RSUs were originally rights to receive ordinary shares of AVITA Medical, Ltd., an Australian public company and predecessor to the Issuer ("Predecessor"). Pursuant to a scheme of arrangement, completed on June 30, 2020, the RSUs became rights to be issued shares of Common Stock of the Issuer in the ratio of one share of Common Stock for every 100 ordinary shares of Predecessor to which the holder would otherwise have been entitled. The RSUs vest on June 1, 2022. F5 · balance_after: 631,525 CDIs, which translate into 126,305 shares of Common Stock, and 50,677 shares of Common Stock were previously transferred to the Reporting Person's former spouse pursuant to a property settlement agreement entered into in connection with a divorce proceeding. The Reporting Person no longer reports as beneficially owned any securities owned by his former spouse. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 23:14 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock Sold | 4,000 | $76.09 | $304,360.00 |
DisclosureSEC source: 0001209191-21-001538 · doc4.xml · nonDerivative · entry 2 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.06 to $76.33, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 01, 2021 Filed Jan 5, 2021 23:14 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-001538 · doc4.xml · nonDerivative · entry 1 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,000 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. Read SEC document |
| September 16, 2020 Filed Sep 16, 2020 23:15 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | SaleCommon Stock | 9,000 | $27.41 | $246,690.00 |
DisclosureSEC source: 0001209191-20-050769 · doc4.xml · nonDerivative · entry 4 PERRY MICHAEL S · CIK 0001250379 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 425,087 F4 · kind: Represents shares sold in order to pay withholding taxes due in connection with the vesting of RSUs. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.30 to $28.20. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of the shares of Common Stock sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · balance_after: Includes 1,266,125 of the Issuer's CHESS Depositary Interests ("CDIs"). CDIs are units of beneficial ownership in shares of common stock of the Issuer that are publicly traded on the Australian Securities Exchange (the "ASX") and held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX. Five CDIs are equivalent to one share of Common Stock and have all the rights and privileges of Common Stock. The Reporting Person holds 1,266,125 CDIs, which translate into 253,225 of the shares of Common Stock set forth above. F3 · balance_after: Includes 95,014 unvested RSUs, each representing a contingent right to be issued one share of Common Stock, that are subject to time-based vesting criteria. These RSUs were originally rights to receive ordinary shares of AVITA Medical, Ltd., an Australian public company and predecessor to the Issuer ("Predecessor"). Pursuant to a scheme of arrangement, completed on June 30, 2020, the RSUs became rights to be issued shares of Common Stock of the Issuer in the ratio of one share of Common Stock for every 100 ordinary shares of Predecessor to which the holder would otherwise have been entitled. The RSUs vest in two equal installments on June 1, 2021 and 2022. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 23:15 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | SaleCommon Stock | 23,769 | $27.23 | $647,229.87 |
DisclosureSEC source: 0001209191-20-050769 · doc4.xml · nonDerivative · entry 3 PERRY MICHAEL S · CIK 0001250379 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 434,087 F4 · kind: Represents shares sold in order to pay withholding taxes due in connection with the vesting of RSUs. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.11 to $27.64. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of the shares of Common Stock sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · balance_after: Includes 1,266,125 of the Issuer's CHESS Depositary Interests ("CDIs"). CDIs are units of beneficial ownership in shares of common stock of the Issuer that are publicly traded on the Australian Securities Exchange (the "ASX") and held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX. Five CDIs are equivalent to one share of Common Stock and have all the rights and privileges of Common Stock. The Reporting Person holds 1,266,125 CDIs, which translate into 253,225 of the shares of Common Stock set forth above. F3 · balance_after: Includes 95,014 unvested RSUs, each representing a contingent right to be issued one share of Common Stock, that are subject to time-based vesting criteria. These RSUs were originally rights to receive ordinary shares of AVITA Medical, Ltd., an Australian public company and predecessor to the Issuer ("Predecessor"). Pursuant to a scheme of arrangement, completed on June 30, 2020, the RSUs became rights to be issued shares of Common Stock of the Issuer in the ratio of one share of Common Stock for every 100 ordinary shares of Predecessor to which the holder would otherwise have been entitled. The RSUs vest in two equal installments on June 1, 2021 and 2022. Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 23:15 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | SaleCommon Stock | 15,092 | $26.99 | $407,333.08 |
DisclosureSEC source: 0001209191-20-050769 · doc4.xml · nonDerivative · entry 2 PERRY MICHAEL S · CIK 0001250379 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 457,856 F4 · kind: Represents shares sold in order to pay withholding taxes due in connection with the vesting of RSUs. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.40 to $27.07. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of the shares of Common Stock sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · balance_after: Includes 1,266,125 of the Issuer's CHESS Depositary Interests ("CDIs"). CDIs are units of beneficial ownership in shares of common stock of the Issuer that are publicly traded on the Australian Securities Exchange (the "ASX") and held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX. Five CDIs are equivalent to one share of Common Stock and have all the rights and privileges of Common Stock. The Reporting Person holds 1,266,125 CDIs, which translate into 253,225 of the shares of Common Stock set forth above. F3 · balance_after: Includes 95,014 unvested RSUs, each representing a contingent right to be issued one share of Common Stock, that are subject to time-based vesting criteria. These RSUs were originally rights to receive ordinary shares of AVITA Medical, Ltd., an Australian public company and predecessor to the Issuer ("Predecessor"). Pursuant to a scheme of arrangement, completed on June 30, 2020, the RSUs became rights to be issued shares of Common Stock of the Issuer in the ratio of one share of Common Stock for every 100 ordinary shares of Predecessor to which the holder would otherwise have been entitled. The RSUs vest in two equal installments on June 1, 2021 and 2022. Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 23:15 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantCommon Stock | 68,504 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-050769 · doc4.xml · nonDerivative · entry 1 PERRY MICHAEL S · CIK 0001250379 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 472,948 F1 · date: These shares of Common Stock were issued in connection with the vesting of Restricted Stock Units ("RSUs"), which were originally granted on November 26, 2019, upon the satisfaction of a performance-based vesting condition. F2 · balance_after: Includes 1,266,125 of the Issuer's CHESS Depositary Interests ("CDIs"). CDIs are units of beneficial ownership in shares of common stock of the Issuer that are publicly traded on the Australian Securities Exchange (the "ASX") and held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX. Five CDIs are equivalent to one share of Common Stock and have all the rights and privileges of Common Stock. The Reporting Person holds 1,266,125 CDIs, which translate into 253,225 of the shares of Common Stock set forth above. F3 · balance_after: Includes 95,014 unvested RSUs, each representing a contingent right to be issued one share of Common Stock, that are subject to time-based vesting criteria. These RSUs were originally rights to receive ordinary shares of AVITA Medical, Ltd., an Australian public company and predecessor to the Issuer ("Predecessor"). Pursuant to a scheme of arrangement, completed on June 30, 2020, the RSUs became rights to be issued shares of Common Stock of the Issuer in the ratio of one share of Common Stock for every 100 ordinary shares of Predecessor to which the holder would otherwise have been entitled. The RSUs vest in two equal installments on June 1, 2021 and 2022. Read SEC document |
| September 11, 2020 Filed Sep 11, 2020 23:59 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | SaleCommon Stock | 20,000 | $26.02 | $520,400.00 |
DisclosureSEC source: 0001209191-20-050215 · doc4.xml · nonDerivative · entry 3 PERRY MICHAEL S · CIK 0001250379 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 404,444 F4 · kind: Represents shares sold in order to pay withholding taxes due in connection with the vesting of RSUs. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.77 to $26.26. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of the shares of Common Stock sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| September 10, 2020 Filed Sep 11, 2020 23:59 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | SaleCommon Stock | 7,128 | $26.26 | $187,181.28 |
DisclosureSEC source: 0001209191-20-050215 · doc4.xml · nonDerivative · entry 2 PERRY MICHAEL S · CIK 0001250379 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 424,444 F4 · kind: Represents shares sold in order to pay withholding taxes due in connection with the vesting of RSUs. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.53. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of the shares of Common Stock sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| September 09, 2020 Filed Sep 11, 2020 23:59 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantStock Options (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $5.99 | $0.00 |
DisclosureSEC source: 0001209191-20-050215 · doc4.xml · derivative · entry 4 PERRY MICHAEL S · CIK 0001250379 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 25,000 shares Expires 2028-11-30 F7 · security: These Stock Options were originally exercisable for ordinary shares of Predecessor. Pursuant to the Scheme, the Stock Options became exercisable for shares of Common Stock of the Issuer in the ratio of one share of Common Stock for every 100 ordinary shares of Predecessor for which the Stock Options would otherwise have been exercisable. F8 · derivative.exercise_price: The exercise price was converted from A$8.20, which reflects the 100:1 consolidation ratio applied in converting ordinary shares of Predecessor to shares of the Issuer's Common Stock, using the exchange rate as published by the Reserve Bank of Australia in effect on the date of grant (November 30, 2018). The actual exercise price will be the Australian dollar amount regardless of the exchange rate on the date of grant or of exercise. F9 · date: On November 30, 2018, the Reporting Person was granted Stock Options to purchase 150,000 shares of Common Stock, vesting based on the satisfaction of certain time-based and performance-based conditions. On September 9, 2020, the performance-based vesting condition with respect to the last 25,000 unvested Stock Options was satisfied. Read SEC document |
| September 09, 2020 Filed Sep 11, 2020 23:59 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantCommon Stock | 83,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-050215 · doc4.xml · nonDerivative · entry 1 PERRY MICHAEL S · CIK 0001250379 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 431,572 F1 · date: These shares of Common Stock were issued in connection with the vesting of Restricted Stock Units ("RSUs"), which were originally granted on November 30, 2018, upon the satisfaction of a performance-based vesting condition. F2 · balance_after: Includes 1,266,125 of the Issuer's CHESS Depositary Interests ("CDIs"). CDIs are units of beneficial ownership in shares of common stock of the Issuer that are publicly traded on the Australian Securities Exchange (the "ASX") and held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX. Five CDIs are equivalent to one share of Common Stock and have all the rights and privileges of Common Stock. The Reporting Person holds 1,266,125 CDIs, which translate into 253,225 of the shares of Common Stock set forth above. F3 · balance_after: Includes 95,014 unvested RSUs, each representing a contingent right to be issued one share of Common Stock, that are subject to time-based vesting criteria. These RSUs were originally rights to receive ordinary shares of AVITA Medical, Ltd., an Australian public company and predecessor to the Issuer ("Predecessor"). Pursuant to a scheme of arrangement, completed on June 30, 2020 (the "Scheme"), the RSUs became rights to be issued shares of Common Stock of the Issuer in the ratio of one share of Common Stock for every 100 ordinary shares of Predecessor to which the holder would otherwise have been entitled. The RSUs vest in two equal installments on June 1, 2021 and 2022. Read SEC document |
| May 14, 2020 Filed May 18, 2020 22:27 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionCommon Stock (right to buy) · Derivative | 25,000 | $0.00 Strike: $4.20 | $0.00 |
DisclosureSEC source: 0001209191-20-030214 · doc4.xml · derivative · entry 12 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2021-12-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents first vesting date. Option vested over four years from date of grant. Read SEC document |
| May 14, 2020 Filed May 18, 2020 22:27 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionCommon Stock (right to buy) · Derivative | 15,000 | $0.00 Strike: $5.19 | $0.00 |
DisclosureSEC source: 0001209191-20-030214 · doc4.xml · derivative · entry 11 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 15,000 shares Expires 2022-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Option vested entirely on the one year anniversary of the grant date. Read SEC document |
| May 14, 2020 Filed May 18, 2020 22:27 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionCommon Stock (right to buy) · Derivative | 10,000 | $0.00 Strike: $2.62 | $0.00 |
DisclosureSEC source: 0001209191-20-030214 · doc4.xml · derivative · entry 10 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 10,000 shares Expires 2022-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Option vested entirely on the one year anniversary of the grant date. Read SEC document |
| May 14, 2020 Filed May 18, 2020 22:27 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionCommon Stock (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-20-030214 · doc4.xml · derivative · entry 9 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 15,000 shares Expires 2023-03-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Option vested entirely on the one year anniversary of the grant date. Read SEC document |
| May 14, 2020 Filed May 18, 2020 22:27 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionCommon Stock (right to buy) · Derivative | 5,000 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001209191-20-030214 · doc4.xml · derivative · entry 8 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 5,000 shares Expires 2023-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Option vested entirely on the one year anniversary of the grant date. Read SEC document |
| May 14, 2020 Filed May 18, 2020 22:27 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionCommon Stock (right to buy) · Derivative | 7,000 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001209191-20-030214 · doc4.xml · derivative · entry 7 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 7,000 shares Expires 2023-09-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Option vested entirely on the one year anniversary of the grant date. Read SEC document |
| May 14, 2020 Filed May 18, 2020 22:27 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionCommon Stock | 25,000 | $4.20 | $105,000.00 |
DisclosureSEC source: 0001209191-20-030214 · doc4.xml · nonDerivative · entry 6 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 14, 2020 Filed May 18, 2020 22:27 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionCommon Stock | 15,000 | $5.19 | $77,850.00 |
DisclosureSEC source: 0001209191-20-030214 · doc4.xml · nonDerivative · entry 5 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 14, 2020 Filed May 18, 2020 22:27 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionCommon Stock | 10,000 | $2.62 | $26,200.00 |
DisclosureSEC source: 0001209191-20-030214 · doc4.xml · nonDerivative · entry 4 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 14, 2020 Filed May 18, 2020 22:27 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionCommon Stock | 15,000 | $2.19 | $32,850.00 |
DisclosureSEC source: 0001209191-20-030214 · doc4.xml · nonDerivative · entry 3 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.